CARIPUL 1.5 MG — DIN 02397455
EPOPROSTENOL (EPOPROSTENOL SODIUM) : 1.5 MG · JANSSEN INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CARIPUL?
CARIPUL 1.5 MG contains EPOPROSTENOL (EPOPROSTENOL SODIUM) : 1.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02397455, held by JANSSEN INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARIPUL used for?
Long-term IV treatment of idiopathic/heritable PAH and PAH associated with connective tissue disease in NYHA Class III and IV patients who failed conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Epoprostenol cost around the world?
Epoprostenol is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Iceland publishes a max wholesale; Slovakia publishes a categorised final price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
6 pack listings across 3 brand entries and 3 price bases, refreshed 08 Sep 2026. Ranges span every Epoprostenol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Epoprostenol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Epoprostenol, across 6 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GLAXOSMITHKLINE INC | 2 | 2 | FLOLAN | Sourceable in Canada |
| JANSSEN INC | 2 | 2 | CARIPUL | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 0 | EPOPROSTENOL FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.5 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 10 mL vials, individually packaged in a carton. Available in 0.5 mg and 1.5 mg strengths. |
| Storage | Do not expose reconstituted or diluted solutions to direct sunlight. (Detailed stability at 25°C and 2-8°C provided in monograph tables). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Epoprostenol |
|---|---|
| ATC code | B01AC09 |
| AHFS class | 48:48.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02397455 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2397455 |
| Brand name | CARIPUL |
| Generic / active ingredient | EPOPROSTENOL (EPOPROSTENOL SODIUM) : 1.5 MG |
| Market authorization holder | JANSSEN INC |
| Health Canada schedule | Prescription |
| ATC code | B01AC09 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AC |
| Current status | MARKETED |
| Status date | 26-May-2020 |
| Original market date | 2013-04-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initiate at 2 ng/kg/min; increase by 2 ng/kg/min every 15+ mins until dose-limiting effects. Chronic delivery via permanent indwelling central venous catheter using an ambulatory pump.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or ingredients; congestive heart failure due to severe left ventricular systolic dysfunction; patients who develop pulmonary edema during dose initiation.
Warnings and precautions
Abrupt withdrawal may result in rebound pulmonary hypertension and death. Potent vasodilator; dose initiation must be in a hospital setting. Risk of tissue damage if extravasation occurs.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARIPUL | 0.5 MG | POWDER FOR SOLUTION | JANSSEN INC | MARKETED | 02397447 |
| FLOLAN | 0.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | 02230845 |
| FLOLAN | 1.5 MG | POWDER FOR SOLUTION | GLAXOSMITHKLINE INC | MARKETED | 02230848 |
| EPOPROSTENOL FOR INJECTION | 0.5 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02345706 |
| EPOPROSTENOL FOR INJECTION | 1.5 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02345714 |
2 · Same class — other molecules in ATC B01AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Clopidogrel | ABBOTT-CLOPIDOGREL · ACCEL-CLOPIDOGREL · ACT CLOPIDOGREL · AG-CLOPIDOGREL · APO-CLOPIDOGREL · AURO-CLOPIDOGREL · BIO-CLOPIDOGREL · CLOPIDOGREL · DOM-CLOPIDOGREL · IPG-CLOPIDOGREL · JAMP-CLOPIDOGREL · M-CLOPIDOGREL · MAR-CLOPIDOGREL · MINT-CLOPIDOGREL · MYLAN-CLOPIDOGREL · NRA-CLOPIDOGREL · PLAVIX · PMS-CLOPIDOGREL · PRIVA-CLOPIDOGREL · Q-CLOPIDOGREL · RBX-CLOPIDOGREL · RIVA-CLOPIDOGREL · SANDOZ CLOPIDOGREL · TARO-CLOPIDOGREL · TEVA-CLOPIDOGREL · TORRENT-CLOPIDOGREL | 39 | 19 | Yes |
| Acetylsalicylic Acid | APO-ASA LD · ASA · ASA 81 MG · ASA DAILY LOW DOSE · ASA EC · ASAPHEN EC · ASPIRIN 81MG · ASPIRIN 81MG QUICK CHEWS · CHEWABLE DAILY LOW DOSE ASA · COATED DAILY LOW DOSE ASA 81 MG · ENTERIC COATED ASA DAILY LOW DOSE · ENTERIC COATED DAILY LOW DOSE ASA 81 MG · ENTROPHEN · ENTROPHEN CHEWABLE · EQUATE DAILY LOW-DOSE · EXACT COATED DAILY LOW-DOSE ASA · JAMP-ASA 81MG EC · LONDON DRUGS COATED DAILY LOW-DOSE ASA · PMS-ASA · PRAXIS ASA EC 81 MG DAILY LOW DOSE · RIVASA 81 MG EC | 23 | 12 | Yes |
| Ticagrelor | AG-TICAGRELOR · APO-TICAGRELOR · BRILINTA · JAMP TICAGRELOR · M-TICAGRELOR · TARO-TICAGRELOR · TEVA-TICAGRELOR | 14 | 12 | Yes |
| Selexipag | UPTRAVI | 8 | 8 | Yes |
| Treprostinil | REMODULIN · TREPROSTINIL INJECTION | 8 | 4 | Yes |
| Epoprostenol | CARIPUL · EPOPROSTENOL FOR INJECTION · FLOLAN | 6 | 4 | Yes |
| Dipyridamole | APO-DIPYRIDAMOLE · APO-DIPYRIDAMOLE-SC TAB 25MG · APO-DIPYRIDAMOLE-SC TAB 50MG · APO-DIPYRIDAMOLE-SC TAB 75MG · DIPYRIDAMOLE 25 TAB 25MG · DIPYRIDAMOLE 50 TAB 50MG · DIPYRIDAMOLE 75 TAB · DIPYRIDAMOLE FOR INJECTION · DIPYRIDAMOLE INJECTION, USP · DIPYRIDAMOLE-25 · DIPYRIDAMOLE-50 · DIPYRIDAMOLE-75 · NOVO-DIPIRADOL SCT 100MG · NOVO-DIPIRADOL TAB 25MG · NOVO-DIPIRADOL TAB 50MG · NOVO-DIPIRADOL TAB 75MG · PERSANTINE · PERSANTINE TAB 100MG · PERSANTINE TAB 25MG · PERSANTINE TAB 50MG · PERSANTINE TAB 75MG | 24 | 2 | Yes |
| Eptifibatide | EPTIFIBATIDE INJECTION · INTEGRILIN | 14 | 2 | Yes |
| Tirofiban | AGGRASTAT | 2 | 1 | Yes |
| Prasugrel | EFFIENT · JAMP PRASUGREL | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AB | Antithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · Heparin, Combinations · Nadroparin · Tinzaparin | 128 | 82 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · Streptokinase · Tenecteplase · Urokinase | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CARIPUL called?
The same molecule, Epoprostenol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Veletri | Latin | Australia |
| Flolan | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.